Prime Medicine, Inc. (PRME) — Financial statements
Income statement, balance sheet, and cash flow for Prime Medicine, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 5↑55.3% | 3 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 7 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | -3↓190.1% | 3 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 161↑3.4% | 155↑5.0% | 148↑70.5% | 87↑22.9% | 71 | |
| General & Administrative Expenses | 52↑4.4% | 50↑15.6% | 43↑45.5% | 30↑114.2% | 14 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 52↑4.4% | 50↑15.6% | 43↑45.5% | 30↑114.2% | 14 | |
| Other Expenses | -7 | 0.00↓100.0% | 14 | 0.00 | 0.00 | |
| Operating Expenses | 206↑0.1% | 205↑0.3% | 205↑75.7% | 117↑38.0% | 84 | |
| Total Costs & Expenses | 213↑3.7% | 205↑0.3% | 205↑75.7% | 117↑38.0% | 84 | |
| Operating Results | ||||||
| Operating Income | -208↓2.9% | -202↑1.1% | -205↓75.7% | -117↓38.0% | -84 | |
| Depreciation & Amortization | 5↓12.1% | 6↑31.7% | 5↑109.2% | 2↑291.5% | 0.57 | |
| EBITDA | -196↑0.3% | -196↓5.2% | -187↓63.3% | -114↓36.2% | -84 | |
| EBIT | -201↑0.7% | -202↓5.8% | -191↓64.1% | -117↓38.0% | -84 | |
| Interest & Other Income | ||||||
| Net Interest Income | 4↑17.8% | 4 | 0.00 | 0.00 | 0.00 | |
| Interest Income | 4↑17.8% | 4 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | -7 | 0.00↑100.0% | -14 | 0.00 | 0.00 | |
| Other Income / Expenses | 7↑9.5% | 7↑3.2% | 6↑202.5% | -6↑92.4% | -81 | |
| Income Before Tax | -201↓2.7% | -196↑1.3% | -198↓61.6% | -123↑26.0% | -166 | |
| Income Tax Expense | 0.00 | 0.00↑100.0% | -0.28↑70.6% | -0.95↓95.1% | -0.49 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -201↓2.7% | -196↑1.1% | -198↓62.6% | -122↑26.3% | -165 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -201↓2.7% | -196↑1.1% | -198↓62.6% | -122↑26.3% | -165 | |
| Bottom-Line Net Income | -201↓2.7% | -196↑1.1% | -198↓39.5% | -142↑22.9% | -184 | |
| EPS (Basic) | -1.35↑18.3% | -1.65↑24.2% | -2.18↓49.1% | -1.46↑24.0% | -1.92 | |
| EPS (Diluted) | -1.35↑18.3% | -1.65↑24.2% | -2.18↓49.1% | -1.46↑24.0% | -1.92 | |
| Weighted Average Shares | 149↑25.4% | 119↑30.4% | 91↓6.4% | 97↑1.5% | 96 | |
| Weighted Average Diluted Shares | 149↑25.4% | 119↑30.4% | 91↓6.4% | 97↑1.5% | 96 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.